Dermira: A Snapshot of Financial Health and Future Prospects
Dermira, a prominent name in the biopharmaceutical industry, specializes in the development and commercialization of therapeutic solutions for dermatologic diseases. As of now, the company's stock stands firm at a price of $18.75, marking a stable phase in its market performance. Operating under the vast umbrella of Eli Lilly and Company, Dermira boasts a dedicated workforce of 333 employees and plays a significant role in the pharmaceutical sector.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
